Abstract Details

Title A Retrospective Analysis of Factors Contributing to Delayed or Missed Treatment With Ocrelizumab in Patients With Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:00 PM-6:00 PM)

Poster/Presentation
Number 18-002

Objective

This study aims to determine the average number of days between initial ocrelizumab prescription to first infusion in patients with multiple sclerosis seen at a single academic center and to identify the factors that contribute to treatment delays.

Background Ocrelizumab is a high-efficacy monoclonal antibody prescribed for treatment of relapsing-remitting and primary progressive multiple sclerosis. Anecdotally, there are numerous cases in which patients prescribed disease-modifying therapy do not receive their first dose until months after initial prescription. Currently, no set standard exists for time from initial prescription to treatment. Understanding of the factors leading to delay is limited in the literature.

Design/Methods We performed a retrospective chart review of 90 patients who received their first ocrelizumab infusion between October 2023 and November 2024 at a Michigan Medicine infusion center. The primary outcome is the average number of days between initial ocrelizumab order to first infusion. Factors contributing to delays were identified via chart review as a secondary outcome and in a qualitative analysis.

Results The average number of days between initial ocrelizumab order to first infusion was 56.6 days. 19 of the 90 individuals who received ocrelizumab greater than 60 days after initial order date were studied as a subset. Of these 19 individuals, 79% were female and 21% were male. 42% had a documented insurance barrier and 47% had listed a socioeconomic barrier around their multiple sclerosis care. 47% delayed their infusion due to preference. 16% were delayed due to lab monitoring.

Conclusions Patients who received their first dose of ocrelizumab over 60 days after the initial order were delayed at least in part due to insurance barriers, lab monitoring, and patient preferences. Almost half of patients had reported at least one socioeconomic barrier. This study highlights the importance of identifying factors that contribute to delays in treatment to provide areas for intervention.

Authors/Disclosures
Lana Sharba, MD (University of Michigan) PRESENTER	Dr. Sharba has nothing to disclose.
Preeta Gupta, MD (University Of Michigan)	Preeta Gupta, MD has nothing to disclose.
Kelly Smith, PhD	Dr. Smith has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Smith has stock in Biohaven Pharmaceuticals.
Tiffany Braley, MD (University of Michigan Medical Center)	Dr. Braley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bluestar BioAdvisors. The institution of Dr. Braley has received research support from NIH. The institution of Dr. Braley has received research support from PCORI. The institution of Dr. Braley has received research support from National Multiple Sclerosis Society.

��ɫ��

��ɫ��